BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
US Department of Justice
Boehringer Ingelheim
Queensland Health
Johnson and Johnson
Daiichi Sankyo
Farmers Insurance
Chinese Patent Office
UBS

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,324,189

« Back to Dashboard

Which drugs does patent 8,324,189 protect, and when does it expire?

Patent 8,324,189 protects ZOMETA and is included in one NDA.

Protection for ZOMETA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: 8,324,189
Title:Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
Abstract: A method of intravenously administering a bisphosphonate to a patient in need of bisphosphonate treatment comprising intravenously administering 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof over a period of 15 minutes to a patient in need of said treatment.
Inventor(s): Galli; Bruno (Seltisberg, CH), Schran; Horst F (Morristown, NJ), Seaman; John J (New Hope, PA)
Assignee: Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Application Number:11/594,410
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 8,324,189

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis ZOMETA zoledronic acid INJECTABLE;IV (INFUSION) 021223-002 Mar 7, 2003 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis ZOMETA zoledronic acid INJECTABLE;IV (INFUSION) 021223-003 Jun 17, 2011 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Argus Health
Julphar
Farmers Insurance
Federal Trade Commission
Express Scripts
Daiichi Sankyo
Cerilliant
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot